High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: A Nationwide Retrospective Study

Dai Chihara, Koji Izutsu, Eisei Kondo, Rika Sakai, Shuichi Mizuta, Kenji Yokoyama, Hiroto Kaneko, Koji Kato, Yuichi Hasegawa, Takaaki Chou, Hiroyuki Sugahara, Hideho Henzan, Hisashi Sakamaki, Ritsuro Suzuki, Junji Suzumiya

    Research output: Contribution to journalArticle

    22 Citations (Scopus)

    Abstract

    The number of elderly patients with diffuse large Bcell lymphoma (DLBCL) continues to increase but the data regarding autologous stem cell transplantation (ASCT) for elderly patients are limited. We analyzed 484 patients, ages 60years or over, diagnosed with relapsed/refractory DLBCL who received ASCT from 1993 to 2010 in the Japan Society for Hematopoietic Cell Transplantation database. Median age was 64years (range, 60 to 78). To evaluate the impact of age at ASCT, patients were classified into 3 groups: those between the ages of 60 to 64, 65 to 69, and 70years or over. Overall nonrelapse mortality (NRM) at day 100, 1year, and 2years was 4.1%, 5.9% and 7.7%, respectively. NRM did not significantly differ among age groups (P=.60). Two-year progression-free survival (PFS) and overall survival (OS) were 48% and 58%, respectively. PFS and OS were significantly longer in patients 60 to 64years old; however, the survival rate was acceptable even in those 70 or over, with a 2-year OS of 46%. ASCT is feasible in selected elderly patients and age alone should not be a contraindication for ASCT. Eligibility should be individualized and identification of a subset of elderly patients at high risk of treatment-related morbidity or mortality warrants investigation.

    Original languageEnglish
    Pages (from-to)684-689
    Number of pages6
    JournalBiology of Blood and Marrow Transplantation
    Volume20
    Issue number5
    DOIs
    Publication statusPublished - Jan 1 2014

    Fingerprint

    Lymphoma, Large B-Cell, Diffuse
    Stem Cell Transplantation
    Retrospective Studies
    Drug Therapy
    Disease-Free Survival
    Survival
    Mortality
    Lymphoma
    Cell Transplantation
    Japan
    Survival Rate
    Age Groups
    Databases
    Morbidity

    All Science Journal Classification (ASJC) codes

    • Hematology
    • Transplantation

    Cite this

    High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma : A Nationwide Retrospective Study. / Chihara, Dai; Izutsu, Koji; Kondo, Eisei; Sakai, Rika; Mizuta, Shuichi; Yokoyama, Kenji; Kaneko, Hiroto; Kato, Koji; Hasegawa, Yuichi; Chou, Takaaki; Sugahara, Hiroyuki; Henzan, Hideho; Sakamaki, Hisashi; Suzuki, Ritsuro; Suzumiya, Junji.

    In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 5, 01.01.2014, p. 684-689.

    Research output: Contribution to journalArticle

    Chihara, D, Izutsu, K, Kondo, E, Sakai, R, Mizuta, S, Yokoyama, K, Kaneko, H, Kato, K, Hasegawa, Y, Chou, T, Sugahara, H, Henzan, H, Sakamaki, H, Suzuki, R & Suzumiya, J 2014, 'High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: A Nationwide Retrospective Study', Biology of Blood and Marrow Transplantation, vol. 20, no. 5, pp. 684-689. https://doi.org/10.1016/j.bbmt.2014.01.025
    Chihara, Dai ; Izutsu, Koji ; Kondo, Eisei ; Sakai, Rika ; Mizuta, Shuichi ; Yokoyama, Kenji ; Kaneko, Hiroto ; Kato, Koji ; Hasegawa, Yuichi ; Chou, Takaaki ; Sugahara, Hiroyuki ; Henzan, Hideho ; Sakamaki, Hisashi ; Suzuki, Ritsuro ; Suzumiya, Junji. / High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma : A Nationwide Retrospective Study. In: Biology of Blood and Marrow Transplantation. 2014 ; Vol. 20, No. 5. pp. 684-689.
    @article{a9e8d8f73ec44c2b9dadcf769601b106,
    title = "High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: A Nationwide Retrospective Study",
    abstract = "The number of elderly patients with diffuse large Bcell lymphoma (DLBCL) continues to increase but the data regarding autologous stem cell transplantation (ASCT) for elderly patients are limited. We analyzed 484 patients, ages 60years or over, diagnosed with relapsed/refractory DLBCL who received ASCT from 1993 to 2010 in the Japan Society for Hematopoietic Cell Transplantation database. Median age was 64years (range, 60 to 78). To evaluate the impact of age at ASCT, patients were classified into 3 groups: those between the ages of 60 to 64, 65 to 69, and 70years or over. Overall nonrelapse mortality (NRM) at day 100, 1year, and 2years was 4.1{\%}, 5.9{\%} and 7.7{\%}, respectively. NRM did not significantly differ among age groups (P=.60). Two-year progression-free survival (PFS) and overall survival (OS) were 48{\%} and 58{\%}, respectively. PFS and OS were significantly longer in patients 60 to 64years old; however, the survival rate was acceptable even in those 70 or over, with a 2-year OS of 46{\%}. ASCT is feasible in selected elderly patients and age alone should not be a contraindication for ASCT. Eligibility should be individualized and identification of a subset of elderly patients at high risk of treatment-related morbidity or mortality warrants investigation.",
    author = "Dai Chihara and Koji Izutsu and Eisei Kondo and Rika Sakai and Shuichi Mizuta and Kenji Yokoyama and Hiroto Kaneko and Koji Kato and Yuichi Hasegawa and Takaaki Chou and Hiroyuki Sugahara and Hideho Henzan and Hisashi Sakamaki and Ritsuro Suzuki and Junji Suzumiya",
    year = "2014",
    month = "1",
    day = "1",
    doi = "10.1016/j.bbmt.2014.01.025",
    language = "English",
    volume = "20",
    pages = "684--689",
    journal = "Biology of Blood and Marrow Transplantation",
    issn = "1083-8791",
    publisher = "Elsevier Inc.",
    number = "5",

    }

    TY - JOUR

    T1 - High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

    T2 - A Nationwide Retrospective Study

    AU - Chihara, Dai

    AU - Izutsu, Koji

    AU - Kondo, Eisei

    AU - Sakai, Rika

    AU - Mizuta, Shuichi

    AU - Yokoyama, Kenji

    AU - Kaneko, Hiroto

    AU - Kato, Koji

    AU - Hasegawa, Yuichi

    AU - Chou, Takaaki

    AU - Sugahara, Hiroyuki

    AU - Henzan, Hideho

    AU - Sakamaki, Hisashi

    AU - Suzuki, Ritsuro

    AU - Suzumiya, Junji

    PY - 2014/1/1

    Y1 - 2014/1/1

    N2 - The number of elderly patients with diffuse large Bcell lymphoma (DLBCL) continues to increase but the data regarding autologous stem cell transplantation (ASCT) for elderly patients are limited. We analyzed 484 patients, ages 60years or over, diagnosed with relapsed/refractory DLBCL who received ASCT from 1993 to 2010 in the Japan Society for Hematopoietic Cell Transplantation database. Median age was 64years (range, 60 to 78). To evaluate the impact of age at ASCT, patients were classified into 3 groups: those between the ages of 60 to 64, 65 to 69, and 70years or over. Overall nonrelapse mortality (NRM) at day 100, 1year, and 2years was 4.1%, 5.9% and 7.7%, respectively. NRM did not significantly differ among age groups (P=.60). Two-year progression-free survival (PFS) and overall survival (OS) were 48% and 58%, respectively. PFS and OS were significantly longer in patients 60 to 64years old; however, the survival rate was acceptable even in those 70 or over, with a 2-year OS of 46%. ASCT is feasible in selected elderly patients and age alone should not be a contraindication for ASCT. Eligibility should be individualized and identification of a subset of elderly patients at high risk of treatment-related morbidity or mortality warrants investigation.

    AB - The number of elderly patients with diffuse large Bcell lymphoma (DLBCL) continues to increase but the data regarding autologous stem cell transplantation (ASCT) for elderly patients are limited. We analyzed 484 patients, ages 60years or over, diagnosed with relapsed/refractory DLBCL who received ASCT from 1993 to 2010 in the Japan Society for Hematopoietic Cell Transplantation database. Median age was 64years (range, 60 to 78). To evaluate the impact of age at ASCT, patients were classified into 3 groups: those between the ages of 60 to 64, 65 to 69, and 70years or over. Overall nonrelapse mortality (NRM) at day 100, 1year, and 2years was 4.1%, 5.9% and 7.7%, respectively. NRM did not significantly differ among age groups (P=.60). Two-year progression-free survival (PFS) and overall survival (OS) were 48% and 58%, respectively. PFS and OS were significantly longer in patients 60 to 64years old; however, the survival rate was acceptable even in those 70 or over, with a 2-year OS of 46%. ASCT is feasible in selected elderly patients and age alone should not be a contraindication for ASCT. Eligibility should be individualized and identification of a subset of elderly patients at high risk of treatment-related morbidity or mortality warrants investigation.

    UR - http://www.scopus.com/inward/record.url?scp=84897960368&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84897960368&partnerID=8YFLogxK

    U2 - 10.1016/j.bbmt.2014.01.025

    DO - 10.1016/j.bbmt.2014.01.025

    M3 - Article

    C2 - 24492141

    AN - SCOPUS:84897960368

    VL - 20

    SP - 684

    EP - 689

    JO - Biology of Blood and Marrow Transplantation

    JF - Biology of Blood and Marrow Transplantation

    SN - 1083-8791

    IS - 5

    ER -